Tag: Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. BMS is a differentiated company, led by BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. Company’smedicines are helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through its R&D organization, BMS have built a sustainable pipeline of potential therapies and partner with external innovation to broaden and accelerate its work.

Big Pharma to Testify in High Drug Pricing Case

While congressional scrutiny on drug pricing is nothing new, the prospect of some of the pharmaceutical industry's highest-profile CEOs testifying on the issue will make for a must-watch event. In ...

Celgene Announce Better-than-Expected Profit

Celgene Corp, which is being bought by Bristol-Myers Squibb Co, reported a better-than-expected fourth-quarter profit on Thursday, driven mainly by higher sales of psoriasis drug Otezla. Bristol-My...

New Deal of Celgene is for Blood Cancers Treatment

Celgene has struck another collaborative deal, even as the large pharmaceutical company is in the process of being folded into the operations of its new owner, Bristol-Myers Squibb. This morning, p...

EMA Approved BMS Kidney Cancer Drug

Bristol-Myers Squibb has claimed a new approval for its immuno-oncology combination of Opdivo and Yervoy, getting a green light from the European Medicines Agency (EMA) for its use in renal cell carci...

BMS to Acquire Celgene for $74b

In a major biopharmaceutical shake-up, Bristol-Myers Squibb has announced that will acquire Celgene for $74 billion. The acquisition will create a combined speciality biopharma company with portfol...

FDA Expands Approval for BMS’s Ph+ ALL Drug

The US Food and Drug Administration (FDA) has expanded the approval of Bristol-Myers Squibb’s (BMS) Sprycel (dasatinib) tablets to include the treatment of newly diagnosed Philadelphia chromosome-posi...

BMS Confirms Deal with Taisho

After protracted speculation, Bristol-Myers Squibb has confirmed it plans to divest its French over-the-counter (OTC) medicines business UPSA to Japan’s Taisho Pharma in a $1.6 billion deal. BMS ha...

Bristol-Myers Squibb starts research collaboration with Eisai

bristol-myers squibb
Bristol-Myers Squibb, Eisai and H3 Biomedicine announced research collaboration focused on H3’s RNA splicing platform.

Bristol-Myers Squibb entered into a clinical trial collaboration with Compugen

Bristol-Myers Squibb Company and Compugen announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugen’s COM701.

Bristol-Myers Squibb and Tsinghua University evolve their collaboration

Bristol-Myers Squibb
Bristol-Myers Squibb Company and Tsinghua University (China), have entered into a collaboration to discover therapeutic agents against novel targets for autoimmune diseases and cancers.

Nativa won a patent dispute with Bristol-Myers Squibb with regard to dasatinib

The Arbitration Court of the Moscow region decided to fully reject the claims filed by Bristol-Myers Squibb Holdings Ireland against Nativa LLC under the case No. A41-87845/2017.

Bristol-Myers Squibb opened its new biologics discovery center

Bristol-Myers Squibb, a global biopharmaceutical company, officially opened the newest building to its Redwood City (California, USA) research and development campus in Woodside Technology Park.

BMS will collaborate with Janssen on a novel cardiovascular therapy

Bristol-Myers Squibb announced a worldwide collaboration with Janssen Pharmaceuticals on a Factor XIa inhibitor program that includes the development and commercialization of Bristol-Myers Squibb’s Factor XIa inhibitor.

Bristol-Myers Squibb started a new collaboration with Nektar Therapautics

Bristol-Myers Squibb Company and Nektar Therapeutics announced a new clinical collaboration to evaluate Bristol-Myers Squibb’s Opdivo (nivolumab) with Nektar’s investigational medicine, NKTR-214

Sirenas started a research collaboration with Bristol-Myers Squibb

Sirenas, a biotechnology company harnessing computational approaches to discover therapeutics derived from the global microbiome, entered into a multi-target research collaboration agreement with Bristol-Myers Squibb Company

Bristol-Myers Squibb joined ORIEN Avatar Research Program

M2Gen announced that Bristol-Myers Squibb Company has joined the Oncology Research Information Exchange Network® Avatar Research Program